Use of a unique mobile medical asset in covid monoclonal antibody treatment

Herman Morchel; David Clark; Leighanne Buenvenida; Chinwe Ogedegbe

doi:10.3390/healthcare9080990

Use of a unique mobile medical asset in covid monoclonal antibody treatment

Herman Morchel
, David Clark
, Leighanne Buenvenida
, Chinwe Ogedegbe

Center for Discovery and Innovation

Hackensack Meridian School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

The COVID-19 pandemic and the subsequent surge of patients presented to emergency departments has forever changed the paradigm of delivering emergency care. The highly infectious nature of the 2019 Novel Coronavirus, or COVID-19, mandated strict environmental changes, novel patient care, and flexible strategies to continue to deliver efficient emergency care while maintaining appropriate physical distancing between suspect and non-suspect COVID-19 patients. The engagement of a unique rapidly deployable Mobile Satellite Emergency Department (MSED) with scalable capability from prompt care to resuscitation level allowed the emergency care team to optimize patient care and throughput. The MSED was strategically located adjacent to the ambulance en-trance. While initially deployed to increase Emergency Department surge capacity, the MSED was repurposed to cohort and treat COVID patients with the monoclonal antibody, Bamlanivimab, who were expected to be discharged after treatment. This allowed for more efficient use of Emergency Department resources, including physical space and staffing.

Original language	English
Article number	990
Journal	Healthcare (Switzerland)
Volume	9
Issue number	8
DOIs	https://doi.org/10.3390/healthcare9080990
State	Published - Aug 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Leadership and Management
Health Policy
Health Informatics
Health Information Management

Keywords

Bamlanivimab
COVID monoclonal antibody treatment
COVID-19
COVID-19 patient isolation
COVID-19 patient treatment area
Mobile Satellite Emergency Department

Access to Document

10.3390/healthcare9080990

Cite this

@article{da8baaf149144f768878e0b21de8cccc,

title = "Use of a unique mobile medical asset in covid monoclonal antibody treatment",

abstract = "The COVID-19 pandemic and the subsequent surge of patients presented to emergency departments has forever changed the paradigm of delivering emergency care. The highly infectious nature of the 2019 Novel Coronavirus, or COVID-19, mandated strict environmental changes, novel patient care, and flexible strategies to continue to deliver efficient emergency care while maintaining appropriate physical distancing between suspect and non-suspect COVID-19 patients. The engagement of a unique rapidly deployable Mobile Satellite Emergency Department (MSED) with scalable capability from prompt care to resuscitation level allowed the emergency care team to optimize patient care and throughput. The MSED was strategically located adjacent to the ambulance en-trance. While initially deployed to increase Emergency Department surge capacity, the MSED was repurposed to cohort and treat COVID patients with the monoclonal antibody, Bamlanivimab, who were expected to be discharged after treatment. This allowed for more efficient use of Emergency Department resources, including physical space and staffing.",

keywords = "Bamlanivimab, COVID monoclonal antibody treatment, COVID-19, COVID-19 patient isolation, COVID-19 patient treatment area, Mobile Satellite Emergency Department",

author = "Herman Morchel and David Clark and Leighanne Buenvenida and Chinwe Ogedegbe",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = aug,

doi = "10.3390/healthcare9080990",

language = "English",

volume = "9",

journal = "Healthcare (Switzerland)",

issn = "2227-9032",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "8",

}

TY - JOUR

T1 - Use of a unique mobile medical asset in covid monoclonal antibody treatment

AU - Morchel, Herman

AU - Clark, David

AU - Buenvenida, Leighanne

AU - Ogedegbe, Chinwe

PY - 2021/8

Y1 - 2021/8

N2 - The COVID-19 pandemic and the subsequent surge of patients presented to emergency departments has forever changed the paradigm of delivering emergency care. The highly infectious nature of the 2019 Novel Coronavirus, or COVID-19, mandated strict environmental changes, novel patient care, and flexible strategies to continue to deliver efficient emergency care while maintaining appropriate physical distancing between suspect and non-suspect COVID-19 patients. The engagement of a unique rapidly deployable Mobile Satellite Emergency Department (MSED) with scalable capability from prompt care to resuscitation level allowed the emergency care team to optimize patient care and throughput. The MSED was strategically located adjacent to the ambulance en-trance. While initially deployed to increase Emergency Department surge capacity, the MSED was repurposed to cohort and treat COVID patients with the monoclonal antibody, Bamlanivimab, who were expected to be discharged after treatment. This allowed for more efficient use of Emergency Department resources, including physical space and staffing.

AB - The COVID-19 pandemic and the subsequent surge of patients presented to emergency departments has forever changed the paradigm of delivering emergency care. The highly infectious nature of the 2019 Novel Coronavirus, or COVID-19, mandated strict environmental changes, novel patient care, and flexible strategies to continue to deliver efficient emergency care while maintaining appropriate physical distancing between suspect and non-suspect COVID-19 patients. The engagement of a unique rapidly deployable Mobile Satellite Emergency Department (MSED) with scalable capability from prompt care to resuscitation level allowed the emergency care team to optimize patient care and throughput. The MSED was strategically located adjacent to the ambulance en-trance. While initially deployed to increase Emergency Department surge capacity, the MSED was repurposed to cohort and treat COVID patients with the monoclonal antibody, Bamlanivimab, who were expected to be discharged after treatment. This allowed for more efficient use of Emergency Department resources, including physical space and staffing.

KW - Bamlanivimab

KW - COVID monoclonal antibody treatment

KW - COVID-19

KW - COVID-19 patient isolation

KW - COVID-19 patient treatment area

KW - Mobile Satellite Emergency Department

UR - https://www.scopus.com/pages/publications/85112331631

U2 - 10.3390/healthcare9080990

DO - 10.3390/healthcare9080990

M3 - Article

SN - 2227-9032

VL - 9

JO - Healthcare (Switzerland)

JF - Healthcare (Switzerland)

IS - 8

M1 - 990

ER -

Use of a unique mobile medical asset in covid monoclonal antibody treatment

Abstract

UN SDGs

ASJC Scopus subject areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this